Atomoxetine in clinical practice

• Strattera approved to treat ADHD. FDA Consum37(2), 4 (2003).
   Google Scholar
• Bymaster FP , KatnerJS, NelsonDLet al.: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology27(5), 699–711 (2002).
   PubMed Web of Science ®Google Scholar
• Kuczenski R , SegalDS: An escalating dose/multiple high-dose binge pattern of amphetamine administration results in differential changes in the extracellular dopamine response profiles in caudate-putamen and nucleus accumbens. J. Neurosci.17(11), 4441–4447 (1997).
   PubMed Web of Science ®Google Scholar
• Kratochvil C , TurgayA, WeissM: High dose atomoxetine for the treatment of ADHD. Poster presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Kelsey DK , SumnerCR, CasatCDet al.: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics114(1), E1–E8 (2004).
   PubMed Web of Science ®Google Scholar
• Kelsey D , SumnerCR, CasatCet al.: Once-daily atomoxetine in childhood ADHD: continuous symptom relief. Presented at the Annual Meeting of the American Psychiatric Association. Atlanta, GA, USA, May 21–26 (2005).
   Google Scholar
• Michelson D , AdlerL, SpencerTet al.: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry53(2), 112–120 (2003).
   PubMed Web of Science ®Google Scholar
• Michelson D , AllenAJ, BusnerJet al.: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry159(11), 1896–1901 (2002).
   PubMed Web of Science ®Google Scholar
• Weiss MD , HechtmanL: Adult ADHD Research Group. A randomized, double-blind trial of paroxetine and/or dextroamphetamine and problem focused therapy for ADHD in adults. J. Clin. Psychiatry (2006) In press.
   Web of Science ®Google Scholar
• Spencer T , BiedermanJ, WilensTet al.: A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry57(5), 456–463 (2005).
   PubMed Web of Science ®Google Scholar
• Spencer TJ : Efficacy and tolerability of long-term, open-label, mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectr.10(Suppl. 15), 14–22 (2005).
   Google Scholar
• Quitkin FM , McGrathPJ, StewartJW, TaylorBP, KleinDF: Can the effects of antidepressants be observed in the first two weeks of treatment?Neuropsychopharmacology15(4), 390–394 (1996).
   PubMed Web of Science ®Google Scholar
• Quitkin FM , McGrathPJ, StewartJWet al.: Chronological milestones to guide drug change. When should clinicians switch antidepressants?Arch. Gen. Psychiatry53(9), 785–792 (1996).
   PubMed Web of Science ®Google Scholar
• Sutton VK , MiltonDR, RuffDD, Allen AJ: Atomoxetine's efficacy over time in children and adolescents with attention-deficit/hyperactivity disorder. Poster presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, USA, October 19–24 (2004).
   Google Scholar
• Adler LA , SpencerTJ, MiltonDR, Moore RJ, Michelson D: Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J. Clin. Psychiatry66(3), 294–299 (2005).
   PubMed Web of Science ®Google Scholar
• Buitelaar JK , DanckaertsM, GillbergCet al.: A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur. Child Adolesc. Psychiatry13(4), 249–257 (2004).
   PubMed Web of Science ®Google Scholar
• Kenner JE , StarrHL, BowenDLet al.: Greater symptom improvement and response rates with OROS methylphenidate vs atomoxetine in children with ADHD. Presented at Collegium Internationale Neuropsychopharmacologicum (CINP) Meeting. Paris, France, June 20–24 (2004).
   Google Scholar
• Wigal SB , McGoughJJ, McCrackenJTet al.: A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J. Atten. Disord.9(1), 275–289 (2005).
   PubMedGoogle Scholar
• Quitkin FM , PetkovaE, McGrathPJet al.: When should a trial of fluoxetine for major depression be declared failed?Am. J. Psychiatry160(4), 734–740 (2003).
   PubMed Web of Science ®Google Scholar
• Montgomery SA , BechP, BlierPet al.: Selecting methodologies for the evaluation of differences in time to response between antidepressants. J. Clin. Psychiatry63(8), 694–699 (2002).
   PubMed Web of Science ®Google Scholar
• Quitkin FM : Placebos, drug effects, and study design: a clinician‘s guide. Am. J. Psychiatry156(6), 829–836 (1999).
   PubMed Web of Science ®Google Scholar
• Bussing R , ZimaBT, MasonD, HouW, GarvanCW, FornessS: Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.15(1), 78–87 (2005).
   PubMed Web of Science ®Google Scholar
• Michelson D : A double-blind, placebo-controlled comparison of atomoxetine, OROS methyphenidate and placebo. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Sumner CR , SherL, SuttonVK, BakkenR, PacakowskiM, KelseyD: Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. Poster presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Kratochvil CJ , NewcornJH, ArnoldLEet al.: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J. Am. Acad. Child Adolesc. Psychiatry44(9), 915–924 (2005).
   PubMed Web of Science ®Google Scholar
• Allen AJ , KurlanRM, GilbertDLet al.: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology65(12), 1941–1949 (2005).
   PubMed Web of Science ®Google Scholar
• Reimherr FW , MarchantBK, StrongREet al.: Emotional dysregulation in adult ADHD and response to atomoxetine. Biol. Psychiatry58(2), 125–131 (2005).
   PubMed Web of Science ®Google Scholar
• Newcorn JH , SpencerTJ, BiedermanJ, MiltonDR, MichelsonD: Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J. Am. Acad. Child Adolesc. Psychiatry44(3), 240–248 (2005).
   PubMed Web of Science ®Google Scholar
• Spencer TJ , NewcornJH, KratochvilCJ, RuffD, MichelsonD, BiedermanJ: Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics116(1), e74–e80 (2005).
   PubMed Web of Science ®Google Scholar
• Swanson J , RuffD, FeldmanPD, FurrA, AllenAJ: Characterization of growth in children with ADHD. Poster presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Sangal RB , OwensJ, AllenAJ: Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Poster presented at the Annual Meeting of the American Professional Sleep Society (APSS). Denver, CO, USA, June 18–23 (2005).
   Google Scholar
• Brown TE : Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J. Child Adolesc. Psychopharmacol.14(1), 129–136 (2004).
   PubMed Web of Science ®Google Scholar
• Wilens T : Mixed amphetamine salts XR (MAS XR) in treated hypertensives with ADHD. Symposium 13C. Poster presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Barkley R , McMurrayM, EdelbrockCS, RobbinsK: Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systematic, placebo-controlled evaluation. Pediatrics86, 184–192 (1990).
   PubMed Web of Science ®Google Scholar
• Polzer J , BangsME, ZhangSet al.: Meta-analysis of aggression or hostility events in atomoxetine pediatric trials. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Read HA , BangsME, LingJet al.: Review of hepatic events associated with atomoxetine treatment of ADHD. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar
• Swanson JM , KraemerHC, HinshawSPet al.: Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J. Am. Acad. Child Adolesc. Psychiatry40(2), 168–179 (2001).
   PubMed Web of Science ®Google Scholar
• Quintana H , KelseyD, CherlinEAet al.: Transitioning from psychostimulants to atomoxetine in ADHD patients. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada, October 18–23 (2005).
   Google Scholar

Websites

• FDA Talk Paper. Safety Information on Strattera (2004) www.fda.gov/bbs/topics/ANSWERS/2004/ANS01335.html
   Google Scholar
• Health Canada Endorsed Important Safety Information Strattera www.hc-sc.gc.ca/dhpmps/alt_formats/hpfbdgpsa/pdf/medeff/strattera_hpc-cps_e.pdf.2005
   Google Scholar